BioCentury
ARTICLE | Clinical News

Colobreathe colistimethate sodium regulatory update

April 1, 2013 7:00 AM UTC

The U.K.'s NICE issued final guidance recommending Colobreathe colistimethate sodium from Forest to treat chronic pulmonary infection caused by Pseudomonas aeruginosa in cystic fibrosis (CF) patients if nebulized colistimethate, a generic antibiotic, is not tolerated or has not produced an adequate clinical response. The recommendation is contingent on Forest providing Colobreathe at an undisclosed discount under a patient access scheme. The guidance is in line with a final appraisal determination (FAD) issued in January (see BioCentury, Jan. 28). ...